Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 14/20 | 0.70 |
| ▸ | GSK3B | P49841 | 7/20 | 0.70 |
| ▸ | QPCT | Q16769 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19733068 | 0.86 | IDH1 (0.59) | IDH1GSK3BQPCT | |
| SCHEMBL1128498 | 0.86 | GSK3B (0.52) | IDH1GSK3B | |
| SCHEMBL3781580 | 0.86 | GSK3B (0.66) | GSK3B | |
| SCHEMBL5754334 | 0.84 | GSK3B (0.67) | IDH1GSK3B | |
| SCHEMBL5757844 | 0.84 | GSK3B (0.67) | GSK3B | |
| SCHEMBL5752565 | 0.84 | GSK3B (0.54) | IDH1GSK3B | |
| SCHEMBL4689265 | 0.84 | GSK3B (0.50) | IDH1GSK3B | |
| SCHEMBL5754325 | 0.84 | GSK3B (0.69) | IDH1GSK3B | |
| SCHEMBL5759256 | 0.82 | GSK3B (0.69) | GSK3B | |
| SCHEMBL4691089 | 0.82 | GSK3B (0.50) | IDH1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | claimed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | claimed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | claimed |
| US-20130337564-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. | 2013-12-19 | — | — | US | claimed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | claimed |
| EP-2283114-A2 | TREATMENT OF PLURIPOTENT CELLS | Centocor Ortho Biotech Inc. (US) | 2011-02-16 | — | — | EP | claimed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | claimed |
| WO-2009132068-A2 | TREATMENT OF PLURIPOTENT CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2009-10-29 | — | — | WO | claimed |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-7439363-B2 | Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors | JANSSEN PARMACEUTICA N.V. (BE) | 2008-10-21 | — | — | US | disclosed |
| US-7439363-B2 | Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors | JANSSEN PARMACEUTICA N.V. (BE) | 2008-10-21 | — | — | US | disclosed |
| US-7439363-B2 | Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors | JANSSEN PARMACEUTICA N.V. (BE) | 2008-10-21 | — | — | US | disclosed |
| EP-1654255-B1 | SUBSTITUTED INDAZOLYL(INDOLYL)MALEIMIDE DERIVATIVES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2005000836-A1 | SUBSTITUTED INDAZOLYL(INDOLYL)MALEIMIDE DERIVATIVES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| US-20050004201-A1 | Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004201-A1 | Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors | MAP2K2, MAP2K6, MAP3K2 | IDH1 717/4885GSK3B 507/4885QPCT 3610/4885 |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | IDH1 830/4885GSK3B 1/4885QPCT 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.